Faruqi and Faruqui, LLP Logo
Share this page

MiMedx Group, Inc. (MDXG)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In MiMedx Group, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ:MDXG) of the April 25, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in MiMedx stock or options between March 7, 2013 and February 19, 2018 and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

The lawsuit has been filed in the U.S. District Court for the Northern District of Georgia on behalf of all those who purchased MiMedx common stock between March 7, 2013 and February 19, 2018 (the “Class Period”).  The case, MacPhee v. MidMex Group, Inc. et al, No. 1:18-cv-00830 was filed on February 23, 2018 and has been assigned to Judge Eleanor Louise Ross.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) MiMedx was engaged in a “channel-stuffing” scheme designed to inappropriately recognize revenue that had not yet been realized; (2) MiMedx lacked adequate internal controls over financial reporting; and (3) as a result, MiMedx’s publicly disseminated financial statements were materially false and/or misleading.

Specifically, on February 20, 2018, MiMedx disclosed an “internal investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices at the Company” and that “Company executives are also reviewing, among other items, the accounting treatment of certain distributor contracts.”  As a result of the aforementioned internal investigation, the Company announced that it would delay the release of its fourth quarter and fiscal year 2017 financial results.

On this news, MiMedx’s share price fell from $14.47 per share on February 16, 2018 to a closing price of $8.75 on February 20, 2018—a $5.72 or a 39.53% drop.

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    MiMedx Group, Inc. (MDXG)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 02/20/2018

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.